NovaBay Pharmaceuticals
About: NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
Employees: 14
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
23% more funds holding
Funds holding: 13 [Q3] → 16 (+3) [Q4]
15% more capital invested
Capital invested by funds: $87.5K [Q3] → $101K (+$13.3K) [Q4]
0.84% more ownership
Funds ownership: 2.58% [Q3] → 3.42% (+0.84%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for NBY.
Financial journalist opinion
Neutral
Business Wire
1 month ago
NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces it will hold a virtual Special Meeting on April 16, 2025, at which stockholders will vote on a proposal for the liquidation and dissolution of the Company under Delaware law, pursuant to the Plan of Complete Liquidation and Dissolution of the Company (the “Dissolution”). The Special Meeting was announced in a preliminary proxy statement on Schedule 14A filed with the S.
Neutral
Business Wire
3 months ago
NovaBay Pharmaceuticals Completes the Sale of its Eyecare Business to PRN and Further Adjourns its Special Meeting of Stockholders on Dissolution Proposal
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces the completion of the sale of its Avenova eyecare business and related assets to PRN Physician Recommended Nutriceuticals, LLC (“PRN”) for $11.5 million (the “Asset Sale”). The Asset Sale, representing substantially all of the assets of the Company, was consummated pursuant to the Asset Purchase Agreement dated September 19, 2024, as amended, which NovaBay stockholders.
Positive
Zacks Investment Research
4 months ago
NovaBay Pharmaceuticals (NBY) Upgraded to Buy: Here's Why
NovaBay Pharmaceuticals (NBY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
Business Wire
4 months ago
NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces that its Reconvened Special Meeting of Stockholders held on December 18, 2024 has been adjourned until January 16, 2025 at 11:00 a.m. Pacific time to provide stockholders additional time to vote on Proposal One and Proposal Two. Both proposals received significant support based on the shares that have been voted by stockholders but have yet to reach the 50% threshold o.
Neutral
Business Wire
4 months ago
NovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special Meeting
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces that Chief Executive Officer Justin Hall has issued the following Letter to Stockholders: To My Fellow Stockholders, You have the opportunity to approve a transaction that I fully support and that our Board of Directors unanimously believes is in your best interest. Through the proposed sale of NovaBay's eyecare business and Avenova® brand to PRN Physician Recommended.
Neutral
Business Wire
5 months ago
NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces that its Special Meeting of Stockholders held on November 22, 2024 has been adjourned until December 18, 2024 at 11:00 a.m. Pacific time to provide stockholders additional time to vote on Proposal One and Proposal Two. Both proposals received significant support based on the shares that have been voted by stockholders but have yet to reach the 50% threshold of favorabl.
Neutral
Business Wire
5 months ago
Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals' Proposals to Authorize the Sale of its Avenova Brand
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces that the largest institutional advisory firm, Institutional Shareholder Services (ISS), has recommended that NovaBay stockholders vote in favor of all of the Company's proxy proposals, specifically to authorize and approve the sale of its eyecare business (the “Asset Sale Proposal”) and approve the voluntary liquidation and dissolution of the Company (the “Dissolution.
Neutral
Business Wire
5 months ago
NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2024. “Avenova sales through the online channel for the quarter increased 14% over the prior year, while we reduced our marketing spend by 25% in the same period as we further optimized our highly efficient digital marketing programs,” said Justin Hall, CEO of NovaBay. “We saw continued momentum in Avenova online sales into the curr.
Neutral
Business Wire
5 months ago
NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) today announces that the Company has accepted a revised transaction proposal from PRN Physician Recommended Nutriceuticals, LLC (“PRN”) to increase the base purchase price for the Company's eyecare business from $9.5 million to $11.5 million. The Company has entered into an amendment (the “Amendment”) to its previously announced Asset Purchase Agreement, dated September 19, 2024.
Neutral
Business Wire
6 months ago
NovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLC
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces that the Company's board of directors has determined that an unsolicited and non-binding offer from Refresh Acquisitions BidCo LLC (“Refresh”) for an affiliate of Refresh to acquire the Company's Avenova® brand and related assets is a “Superior Proposal” to the Company's asset purchase agreement with PRN Physician Recommended Nutriceuticals, LLC (“PRN”). Refresh's unso.
Charts implemented using Lightweight Charts™